Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
Top Cited Papers
- 27 November 2015
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (1), 48-56
- https://doi.org/10.1016/s1470-2045(15)00438-6
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphomaBritish Journal of Haematology, 2015
- How to manage mantle cell lymphomaLeukemia, 2014
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell MalignancyInternational Reviews of Immunology, 2012
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseBlood, 2012
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainImmunological Reviews, 2009
- Advances in the understanding of mantle cell lymphomaBritish Journal of Haematology, 2008
- The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspectiveImmunological Reviews, 2000